Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.97B | 19.80B | 19.29B | 17.60B | 15.56B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.97B | 19.80B | 19.29B | 17.60B | 15.56B |
| Cost of Revenue | 3.27B | 3.58B | 3.37B | 3.01B | 2.45B |
| Gross Profit | 19.71B | 16.22B | 15.92B | 14.59B | 13.11B |
| SG&A Expenses | 3.43B | 2.93B | 3.46B | 2.63B | 2.75B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.52B | 10.02B | 10.63B | 9.10B | 8.54B |
| Operating Income | 12.46B | 9.78B | 8.66B | 8.50B | 7.02B |
| Income Before Tax | 9.25B | 8.85B | 8.27B | 7.23B | 6.78B |
| Income Tax Expenses | 2.15B | 1.45B | 1.63B | 1.65B | 1.12B |
| Earnings from Continuing Operations | 7.10B | 7.40B | 6.64B | 5.58B | 5.66B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.10B | 7.40B | 6.64B | 5.58B | 5.66B |
| EBIT | 12.46B | 9.78B | 8.66B | 8.50B | 7.02B |
| EBITDA | 12.99B | 10.29B | 9.25B | 8.97B | 7.50B |
| EPS Basic | 7.95 | 8.27 | 7.39 | 6.22 | 6.30 |
| Normalized Basic EPS | 8.91 | 6.79 | 6.19 | 5.72 | 4.82 |
| EPS Diluted | 7.94 | 8.26 | 7.39 | 6.21 | 6.29 |
| Normalized Diluted EPS | 8.90 | 6.78 | 6.19 | 5.71 | 4.81 |
| Average Basic Shares Outstanding | 892.40M | 894.50M | 898.00M | 896.90M | 897.90M |
| Average Diluted Shares Outstanding | 893.70M | 895.90M | 898.00M | 898.80M | 899.80M |
| Dividend Per Share | 1.73 | 1.73 | 1.50 | 1.50 | 1.50 |
| Payout Ratio | 21.79% | 20.93% | 20.27% | 24.10% | 23.79% |